Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.

Taha, Mohamad B; Yahya, Tamer; Satish, Priyanka; Laird, Rachel; Agatston, Arthur S; Cainzos-Achirica, Miguel; Patel, Kershaw V; Nasir, Khurram

Taha, Mohamad B; Yahya, Tamer; Satish, Priyanka; Laird, Rachel; Agatston, Arthur S; Cainzos-Achirica, Miguel; Patel, Kershaw V; Nasir, Khurram.

Afiliación

Taha MB; Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA.
Yahya T; Center for Outcomes Research, Houston Methodist, Houston, TX, USA.
Satish P; Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA.
Laird R; Center for Outcomes Research, Houston Methodist, Houston, TX, USA.
Agatston AS; Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA.
Cainzos-Achirica M; Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA.
Patel KV; Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Nasir K; Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX77030, USA.

Curr Atheroscler Rep ; 24(8): 643-654, 2022 08.

Article en En | MEDLINE | ID: mdl-35624390

Asunto(s)

Diabetes Mellitus Tipo 2; Manejo de la Obesidad; Diabetes Mellitus Tipo 2/tratamiento farmacológico; Receptor del Péptido 1 Similar al Glucagón/agonistas; Receptor del Péptido 1 Similar al Glucagón/uso terapéutico; Humanos; Hipoglucemiantes/uso terapéutico; Liraglutida/uso terapéutico; Obesidad/complicaciones; Obesidad/tratamiento farmacológico; Pérdida de Peso

Palabras clave

Cardiovascular risk factors; Glucagon-like peptide 1 receptor agonists; Liraglutide; Obesity; Semaglutide; Weight loss

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Manejo de la Obesidad Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Curr Atheroscler Rep Asunto de la revista: ANGIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google